Diadexus (DDXSQ) Stock Price, News & Analysis

Diadexus, Inc., a diagnostics company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company's PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure. The company markets its products to various national and regional clinical reference laboratories and hospitals in the United States, Europe, and internationally. The company is based in Poway, California. On June 13, 2016, Diadexus, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.